Please complete the ABSTRACT TEMPLATE online, for Biomed 2023 Company Presentations

Company name: Imagene*   Website: https://imagene-ai.com *
CEO name: Dean Bitan*

Topic: Can we Successfully Diagnose and Guide Patients' Optimal Cancer Treatment?

○ **Executive Summary / Investment Rational**

Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.

Imagene is a leader in AI-based precision oncology, using digitized biopsy images to profile cancer biomarkers in real-time. Our molecular diagnostic solutions streamline cancer care and accelerate diagnosis through immediate, image-based biomarker profiling. Imagene is an award-winning company with a diverse team of data scientists, biologists, software engineers, and medical experts collaborating with top-tier medical centers and pharmaceutical companies globally. (60 words)

○ **Core Technology**

What is the technology, its uniqueness, and its value proposition?

Imagene's proprietary AI algorithms analyze H&E images to provide fast, accurate molecular biomarker profiling. A Wide range of generalized AI models detecting 28 cancer biomarkers across 8 body organs, with high accuracy validated AUC over 0.92. The technology can identify mutations, fusions, differential gene expression, and cancer signatures within minutes from the biopsy image alone. (57 words)

○ **Product Profile/Pipeline**

Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.

Imagene collaborates with top-tier medical centers, genomic labs, and pharma companies to validate and commercialize its AI-based biomarker profiling solution. The digitization of labs and hospitals in recent years creates a significant market opportunity for Imagene, with the potential to democratize precision medicine and improve cancer care. Imagene is well-positioned to make a significant impact on cancer diagnosis. (58 words)

○ **Business Strategy**

Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.

Imagene's business strategy is to expand its AI-based molecular diagnostic solutions to more labs in the clinical setting, providing value to cancer patients worldwide. The company plans to generate short-term and long-term revenues by licensing its technology to labs and hospitals, forming strategic partnerships with pharma companies, and offering additional services to healthcare providers. (54 words)

○ **What's Next?**

R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans

Imagene is actively developing new AI models to expand its molecular diagnostic portfolio. The company is undergoing regulatory processes in order to enable widespread adoption in the clinical settings around the world. In addition, Imagene is committed to investing in its team and infrastructure to support continued growth and to provide value to cancer patients around the world. (59 words)